placebo + sitagliptin

Sitagliptin is an oral small molecule drug in the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used to manage type 2 diabetes mellitus by increasing levels of incretin hormones (GLP-1 and GIP), which stimulate insulin release and decrease glucagon secretion in a glucose-dependent manner. This results in improved blood sugar control. Sitagliptin is not indicated for type 1 diabetes or diabetic ketoacidosis[1][2][3][5]. Placebo refers to an inactive substance used as a control in clinical trials and has no therapeutic effect. The combination "placebo + sitagliptin" typically refers to a clinical trial arm where patients receive both placebo (for another agent) and active sitagliptin, but it does not represent a marketed fixed-dose combination product or unique pharmaceutical entity.